osimertinib
astrazeneca
['lcsm,(-blcsm)']
 reports that neoadjuvant osi in early stage #lcsm only yielded mpr in 15% of patients at #asco2023. surprising.
I am physician and researcher passionate about advancing precision oncology and lung cancer treatments. Views are my own.